AMEX:NNVC (USA) Also trade in: Germany

Nanoviricides Inc

$ 0.25 -0.01 (-3.81%)
Volume: 56,169 Avg Vol (1m): 270,771
Market Cap $: 19.19 Mil Enterprise Value $: 14.96 Mil
P/E (TTM): 0.00 P/B: 1.41
Earnings Power Value -0.24
Net Current Asset Value 0.03
Tangible Book 0.17
Projected FCF -1.06
Median P/S Value 0
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 6/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt No Debt
Cash-To-Debt ranked higher than
93.36% of 859 companies
in the Drug Manufacturers - Major industry.
Industry Max: 91151, Med: 2.03, Min: -0.01
NNVC: No Debt
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 2.05, Med: 10000, Max: 10000
Current: 10000
2.05
10000
Interest Coverage No Debt
Interest Coverage ranked lower than
100.00% of 648 companies
in the Drug Manufacturers - Major industry.
Industry Max: 2689668, Med: 86.08, Min: 0.01
NNVC: No Debt
Ranked among companies with meaningful Interest Coverage only.
N/A
Piotroski F-Score 2
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -5.28
DISTRESS
GREY
SAFE
WACC vs ROIC %
ROIC -92.51%
WACC 19.95%

Profitability & Growth : 4/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
ROE % -49.55
ROE ranked lower than
83.29% of 832 companies
in the Drug Manufacturers - Major industry.
Industry Max: 316.96, Med: 5.94, Min: -3119.47
NNVC: -49.55
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -190.31, Med: -64.65, Max: -7.97
Current: -49.55
-190.31
-7.97
ROA % -44.35
ROA ranked lower than
83.70% of 871 companies
in the Drug Manufacturers - Major industry.
Industry Max: 943.36, Med: 2.88, Min: -1851.14
NNVC: -44.35
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -124.77, Med: -46.09, Max: -4.99
Current: -44.35
-124.77
-4.99
ROC (Joel Greenblatt) % -73.50
ROC (Joel Greenblatt) ranked lower than
76.73% of 855 companies
in the Drug Manufacturers - Major industry.
Industry Max: 34233.33, Med: 11.23, Min: -2671900
NNVC: -73.5
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -1436.16, Med: -432.63, Max: 18.64
Current: -73.5
-1436.16
18.64
3-Year EPS w/o NRI Growth Rate -13.00
3-Year EPS w/o NRI Growth Rate ranked higher than
59.58% of 663 companies
in the Drug Manufacturers - Major industry.
Industry Max: 385.8, Med: 8.9, Min: -403.2
NNVC: -13
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: -227.1, Med: -10.7, Max: 15.7
Current: -13
-227.1
15.7

» NNVC's 30-Y Financials

Financials (Next Earnings Date: 2019-08-21 Est.)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with AMEX:NNVC

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Drug Manufacturers » Drug Manufacturers - Major    NAICS : 325412    SIC : 2834
Compare ASX:RCE OSL:NAVA ASX:PAB ROCO:4172 BOM:500009 AMEX:CPHI ROCO:4102 DHA:ORIONINFU OSTO:AROC BOM:524280 BOM:524518 BOM:533543 BOM:532305 NAS:ALQA ASX:ANP BOM:524470 OSTO:NVP ASX:IDT LSE:SAR XTER:SAC
Traded in other countries NV3N.Germany
Address 1 Controls Drive, Shelton, CT, USA, 06484
Nanoviricides Inc is a nano-biopharmaceutical company which is engaged in discovering, developing and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through an in-licensing strategy.

Ratios

Current vs industry vs history
PB Ratio 1.41
PB Ratio ranked higher than
83.15% of 819 companies
in the Drug Manufacturers - Major industry.
Industry Max: 227.39, Med: 2.64, Min: 0.05
NNVC: 1.41
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 0, Med: 0, Max: 4.45
Current: 1.41
0
4.45
EV-to-EBIT -1.90
EV-to-EBIT ranked lower than
100.00% of 572 companies
in the Drug Manufacturers - Major industry.
Industry Max: 1015380.11, Med: 17.85, Min: 0.13
NNVC: -1.9
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -10.27, Med: 0, Max: 0
Current: -1.9
-10.27
0
EV-to-EBITDA -2.09
EV-to-EBITDA ranked lower than
100.00% of 597 companies
in the Drug Manufacturers - Major industry.
Industry Max: 341528.02, Med: 15.24, Min: 0.12
NNVC: -2.09
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -11.14, Med: 0, Max: 0
Current: -2.09
-11.14
0
Current Ratio 4.27
Current Ratio ranked higher than
65.50% of 855 companies
in the Drug Manufacturers - Major industry.
Industry Max: 413.44, Med: 2.39, Min: 0.02
NNVC: 4.27
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 1.13, Med: 4.6, Max: 71.34
Current: 4.27
1.13
71.34
Quick Ratio 4.27
Quick Ratio ranked higher than
70.18% of 855 companies
in the Drug Manufacturers - Major industry.
Industry Max: 413.44, Med: 1.87, Min: 0.02
NNVC: 4.27
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 1.13, Med: 4.6, Max: 71.34
Current: 4.27
1.13
71.34

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -6.50
3-Year Share Buyback Rate ranked higher than
51.31% of 571 companies
in the Drug Manufacturers - Major industry.
Industry Max: 100, Med: -5.3, Min: -815
NNVC: -6.5
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -10, Med: -6.5, Max: -5
Current: -6.5
-10
-5

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 1.45
Price-to-Tangible-Book ranked higher than
86.38% of 749 companies
in the Drug Manufacturers - Major industry.
Industry Max: 972.22, Med: 3.33, Min: 0.05
NNVC: 1.45
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 1.03, Med: 10.4, Max: 595.71
Current: 1.45
1.03
595.71
Earnings Yield (Joel Greenblatt) % -52.63
Earnings Yield (Greenblatt) ranked lower than
97.46% of 867 companies
in the Drug Manufacturers - Major industry.
Industry Max: 769.23, Med: 3.31, Min: -333.33
NNVC: -52.63
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -122.81, Med: 0, Max: 555.74
Current: -52.63
-122.81
555.74

More Statistics

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 2
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA N
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N